HIV / AIDS in the News

BHIVA guidelines for adults (2025 interim update) - European AIDS Treatment Group

 

UM helps keep HIV program in Kenya running following U.S. funding cuts - UM Today News

 

A Day of Action to End Violence Against Women Living With HIV - POZ - Health, Life and HIV

 

CVS reportedly cites pricing concerns in excluding coverage for Gilead’s new HIV drug - Seeking Alpha

 

What’s the Guidance on COVID Vaccine Boosters for People With HIV? - TheBody

 

EACS 2025: New European HIV guidelines address sleep, obesity and breastfeeding - European AIDS Treatment Group

 

EACS 2025: Second Berlin patient has unusual immune response that seems to have removed his HIV - European AIDS Treatment Group

 

EACS 2025: Three ways Ukraine is using AI to improve HIV services - European AIDS Treatment Group

 

EACS 2025: Hepatitis B reactivation is rare after switching from tenofovir, two European studies show - European AIDS Treatment Group

 

Gilead discontinues early-stage trial for long-acting injectable for HIV - Seeking Alpha

 

Gilead Sciences stock rating reiterated by RBC amid HIV drug setback - Investing.com

 

Why is HIV pre-exposure prophylaxis struggling to find a home in UK primary healthcare? - The Pharmaceutical Journal

 

CORE Knowledge Hub Webinar # 6 | How to Find Money for Your Local HIV Organisation: Tips from a Community-Based Perspective - European AIDS Treatment Group

 

HIVMA HIV Research IDWeek 2025 Anna Person - Pharmacy Practice News

 

HIV/AIDS funding cuts force Philadelphia programs to scale back services - Philadelphia Gay News

 

Mpox in 2025: What You Need to Know - HRC | Human Rights Campaign

 

CVS Caremark tells AIDS activists Gilead needs to lower the price of its new HIV drug to get on formularies - statnews.com

 

IDWeek 2025: HIV Prevention Breakthrough Could Cost $25 Annually - European Medical Journal

 

HBV Reactivation Risk Low After Tenofovir Cessation in HIV - Medscape

 

ViiV Healthcare receives NICE recommendation for HIV prevention therapy - PMLiVE

 

Generically Priced PrEP Lenacapavir Could Help End HIV Epidemic by 2030 - Medscape

 

Weekly Oral HIV Treatment Looks Good at Two Years - POZ - Health, Life and HIV

 

Study: Rate of Dermatologic Disease in HIV Plunges, but Some Groups Remain Vulnerable - Medscape

 

Development and validation of a self-management intervention for adolescents living with HIV in Namibia - Nature

 

Virginia patients, nonprofits cope with loss of federal funding for HIV/AIDS patients - Virginia Mercury

 

Virginia patients, nonprofits cope with loss of federal funding for HIV/AIDS patients - CBS 19 News

 

Virginia patients, nonprofits cope with loss of federal funding for HIV/AIDS patients - Yahoo

 

Hepatitis B vaccination status and associated factors among people living with HIV in Gulu, Uganda: a cross-sectional study - BMC Public Health

 

How Did a Gay Church Embrace the Identity of “a Church with AIDS”? - Slate

 

Resistance following failure of injectable cabotegravir/rilpivirine may limit future treatment options - Aidsmap